Evidence map›Paper›PMID 39572739›Full record

Trial reportScientific reports2024

Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial.

Ramin Nourinia, Sare Safi, Mehrad Mohammadpour, Hamid Riazi-Esfahani, Mohammad Reza Ansari Astaneh, Khalil Ghasemi Falavarjani, Alireza Ramezani, Saeed Karimi, Sahba Fekri, Nazanin Ebrahimiadib and 21 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04482543 (Repeated Intra-silicone Oil Injection of Methotrexate for Management of Proliferative Vitreoretinopathy Grade C; A Multi-center Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04482543 phase2 / phase3unknown statusnot on this map

Repeated Intra-silicone Oil Injection of Methotrexate for Management of Proliferative Vitreoretinopathy Grade C; A Multi-center Study

TypeinterventionalSponsorShahid Beheshti University of Medical SciencesRan2020 to 2021Enrolled74ConditionsProliferative VitreoretinopathyArmsMethotrexate
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Ramin Nourinia *Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran.
Sare Safi *Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mehrad MohammadpourOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran.
Hamid Riazi-EsfahaniTranslational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Reza Ansari AstanehEye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Khalil Ghasemi FalavarjaniEye Research Center, The five Senses Health Institute, Moheb Kowsar Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Alireza RamezaniOphthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Saeed KarimiOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran.
Sahba FekriOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran.
Nazanin EbrahimiadibTranslational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Elias Khalili PourTranslational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Homayoun NikkhahOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran.
Nasser ShoeibiEye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Narges HassanpoorRetina & Vitreous Service, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Maryam HosseiniEye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mojtaba AbrishamiEye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Fatemeh AbdiEye Research Center, The five Senses Health Institute, Moheb Kowsar Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Anoushiravan RahimiNegah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Hossein Jabbarpoor BonyadiHakiman-e Noor Eye Hospital, Tabriz, Iran.
Siamak MoradianOphthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sina Khosravi MirzaeiOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran.
Hamid SafiOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran.
Pasha AnvariEye Research Center, The five Senses Health Institute, Moheb Kowsar Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Kaveh FadakarTranslational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Masoud MirghorbaniTranslational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Niloufar MohammadbagheriOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran.
Firouze HatamiOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran.
Bahareh KheiriOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran.
Mehdi YaseriDepartment of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Zahra KhorramiOphthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hamid AhmadiehOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, 16666, Iran. hahmadieh@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this randomized controlled trial, we assessed the effects of three consecutive intra-silicone oil (SO) injections of methotrexate (MTX) on the outcomes of surgery for proliferative vitreoretinopathy grade C (PVR-C). Seventy-four eyes of 74 patients with PVR-C were included. Of these, 37 eyes were assigned to the MTX group and 37 eyes to the control group. Fourteen patients failed to comply with the 6-month follow-up period. All eyes underwent vitrectomy and SO injection. In the MTX group, 250 µg MTX was injected into the SO after surgery and at weeks 3 and 6 postoperatively. The primary outcome was the retinal reattachment rate at 6 months. The secondary outcomes included limited PVR recurrence and adverse events. Retinal reattachment was achieved in 22 eyes (73.3%) in the MTX group and 23 eyes (76.7%) in the control group (difference: -3.4%, 95% CI: -25.2-18.5%). Limited PVR recurrence was observed in one eye (4.5%) in the MTX group versus nine eyes (39.1%) in the control group at 6 months (P = 0.01). No adverse effects were observed. Adjunctive treatment with three consecutive applications of intra-SO MTX did not reveal a significant effect on the retinal re-detachment rate but could statistically significantly reduce limited PVR recurrence.Trial registration: http//ClinicalTrials.gov NCT04482543, 22/07/2020.

Indexed as

MethotrexateSilicone OilsVitrectomyVitreoretinopathy, ProliferativeAdultAgedFemaleHumansMaleMiddle AgedTreatment OutcomeMethotrexateSilicone OilsMethotrexateProliferative vitreoretinopathyRandomized controlled trial

Identifiers

PMID39572739
PMCPMC11582663

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.